Recent Updates
Recently added Catalysts
CLDX

Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody Day

Key Takeaway: NEEDHAM, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will present an overview of the Company's antibody technology and pipeline at the Credit Suisse An

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

NEEDHAM, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will present an overview of the Company's antibody technology and pipeline at the Credit Suisse Antibody Day on Friday, May 10, 2013 at 11:00 am ET in New York.
A live webcast of the presentation will be available online on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for 30 days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit http://www.celldextherapeutics.com.
Last updated: May 6, 2013